High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076732 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Majdolen Istaiti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel. Hauptthemen laut MEDLINE: Gaucher Disease, Ambroxol, COVID-19. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda (Japan), Takeda Pharmaceuticals International AG.
Abstract (Originalsprache)
Ambroxol hydrochloride (ABX), an oral mucolytic drug available over the counter for many years, acts as a pharmacological chaperone for mutant glucocerebrosidase, albeit at higher doses. Proof-of-concept reports have been published over the past decade on all three types of Gaucher disease (GD). Here, we assess the safety and efficacy of 12 months of 600 mg ambroxol per day in three groups of Type 1 GD patients with a suboptimal response to enzyme replacement therapy (ERT) or substrate reduction therapy (SRT), defined as platelet count < 100 × 103/L, lumbar spine bone density T-score < −2.0, and/or LysoGb1 > 200 ng/mL, and for a group of naïve patients who had abnormal values in two of these three parameters. We enrolled 40 patients: 28 ERT- or SRT-treated, and 12 naïve. There were no severe adverse effects (AEs). There were 24 dropouts, mostly due to AEs (n = 12), all transient, and COVID-19 (n = 7). Among the 16 completers, 5 (31.2%) had a >20% increase in platelet count, 6 (37.5%) had a >0.2 increase in T-score, and 3 (18.7%) had a >20% decrease in Lyso-Gb1. This study expands the number of patients exposed to high-dose ABX, showing good safety and satisfactory efficacy, and provides an additional rationale for adding off-label ABX to the arsenal of therapies that could be offered to patients with GD1 and a suboptimal response or those unable to receive ERT or SRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
- Peter MacCallum Center, Royal Melbourne Hospital, Department of Medicine, University of Melbourne, Melbourne, VIC 3050, Australia.
- Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel.
ORCID-Profile: Majdolen Istaiti, Jeff Szer, Shoshana Revel-Vilk, Ari Zimran
Förderung
- Takeda (Japan)
- Takeda Pharmaceuticals International AG
Zitieren
APA
Istaiti, M., Frydman, D., Dinur, T., Szer, J., Revel-Vilk, S., & Zimran, A. (2023). High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076732
Vancouver
Istaiti M, Frydman D, Dinur T, Szer J, Revel-Vilk S, Zimran A. High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076732
BibTeX
@article{Istaiti2023,
author = {Istaiti, Majdolen and Frydman, Dafna and Dinur, Tama and Szer, Jeff and Revel-Vilk, Shoshana and Zimran, Ari},
title = {High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076732}
}
EUVIMED